
Mechanisms induced by rosmarinic acid in different cancer cell lines (in vitro)
Cancer type | Cell Line | Treatment concentrations | Mechanism of action | References |
---|---|---|---|---|
HCC | Hep-G2 | 0-320 µM | Induction of apoptosis, caspase activation and inhibition of cell migration and invasion | Jin et al., 2020 |
SMMC-7721 | 0-100 µmol/L | Inhibit PI3K/AKT pathway | Wang et al., 2019 | |
Hep-G2 | 100, 200 and 400 µM | Inhibits PI3K/Akt/NF- κB pathway | An et al., 2021 | |
CRC |
CT26 HCT116 |
0-200 µM | Activation of AMPK | Han et al., 2018 |
HT-29 | - | Inhibition of p38/AP-1 pathway and EMT by miR-1225-5p | Yang et al., 2021 | |
HCT-8 HCT-116 |
0,75 and 150 µmol/L | Suppression of miR-155 leading to an anti-Warburg effect | Xu et al., 2016 | |
Pancreatic cancer |
PATU-8988 MIA PaCa-2 Panc-1 BxPC-3 |
0-600 µM | Inhibition of Gli1 expression and target proteins | Zhou et al., 2022 |
Panc-1 SW1990 |
0-200 µM | Elevated expression of miR-506 | Han et al., 2019 | |
Breast cancer |
MDA-MB-468 MDA-MB-231 |
0-500 µM | Modulating extrinsic and intrinsic caspase-independent apoptosis | Messeha et al., 2020 |
MCF-7 | 1.5, 15 and 50 µM | Hindering MDM2, negative regulator of p53 | Juskowiak et al., 2018 | |
Ovarian cancer | OVCAR-3 | 0-160 µM |
Regulation of lncRNA MALAT-1 |
Zhang et al., 2018 |
SKOV-3 TOV-21G |
0, 20 and 40 µM (RAME) | Inhibiting FOXM1 and FOXM1 target genes | Lim et al., 2020 | |
Cervical cancer |
HeLa SiHa |
0-80 µM (RAME) | Inhibition of mTOR/S6K1 pathway | Nam et al., 2019 |
Renal carcinoma | 786-O | 0, 25, 50, and 100 μM | Downregulated FAK phosphorylation | Su et al., 2016 |
NSCLC |
A549 A549 DPP (cisplatin-resistant) |
0-200 µg/mL | Activation of JNK pathway | Liao et al., 2020 |
Gastric cancer | SGC7901/5-Fu | 12.5 to 100 µg/mL | Reversal of chemoresistance by inhibiting miR-6785-5p | Yu et al., 2019 |
MKN45 | 0-600 µM | miR-155 mediated inhibition of the Warburg effect | Han et al., 2015 | |
Prostate cancer |
PC-3 DU-145 |
25-300 µM | Inhibition of HDAC2 | Jang et al., 2018 |
Oral cancer | SCC-15 | 0-180 µM | Oxidative ER stress | Luo et al., 2020 |
Glioma |
U251 U343 |
0, 100, 200 and 400 µM | Inhibition of PI3K/Akt/NF-κB | Liu et al., 2021 |
U-78 MG | 0-1000 µM | HSP27 suppression | Şengelen and Önay-Uçar, 2018 | |
Osteosarcoma |
MG63 U2OS |
0, 12.5, 25, and 50 µg/mL | Suppression of oncogene DJ-1 | Ma et al., 2020 |
Melanoma | A375 | 0, 50, 100 and 200 µg/mL | Suppress ADAM17 expression | Huang et al., 2021 |
Leukemia | NP4 | 40 µM | Enhance ARTA-induced macrophage differentiation | Heo et al., 2015 |
CCRF-CEM Resistant CEM/ADR500 |
3-100 µM | Inhibition of NF- κB | Wu et al., 2015 |